Osel’s approach is to treat dysbiosis by repopulating the microbiome with beneficial bacteria to restore a healthy and protective microbiota.
The primary focus of our work is women’s health, with indications including bacterial vaginosis, obstetric complications, and recurrent urinary tract infections. Other areas of interest include disorders of the gastrointestinal tract and oncology. Our product pipeline is demonstrating exciting therapeutic potential, with two clinical stage products and ongoing clinical trials.
Peter P. Lee, Founder and Executive Chairman
Dr. Lee has published more than 100 articles in peer-reviewed journals and received significant grant awards from the National Institutes of Health, US Department of Defense, and Stand Up To Cancer. He is an elected member of the American Society for Clinical Investigation.
Laurel A. Lagenaur, PhD, Director of Research
Tom Parks, PhD, Director of Product Development
Michael Cannon, Board Member
Sandy Chau, Board Member
Robert Lee, Board Member
Craig Cohen, MD, MPH
Craig R. Cohen, MD, MPH is one of the leading reproductive infectious disease experts in the world. He is professor of obstetrics, gynecology & reproductive sciences at the University of California San Francisco (UCSF), and co-director of the University of California Global Health Institute. Dr. Cohen has collaborated with Osel Inc. since 2007 in the clinical development of LACTIN-V through Phase 1, 2a, and 2b studies. In addition, he served as principal investigator of a grant from NIAID/NIH for the pre-clinical development of MucoCept-CVN, the lead MucoCept product candidate.
Dr. Cohen has over 28 years of experience leading clinical and translational investigations to improve women’s reproductive health. His work focuses on two major areas: 1) development of live biotherapeutic products, like LACTIN-V and MucoCept-CVN, to prevent bacterial vaginosis and its sequelae, and 2) HIV care and prevention research in developing countries.
Dr. Cohen completed his MD at the University of Louisville, obstetrics & gynecology residency at Northwestern University, and fellowship in reproductive infectious disease and Masters of Public Health at the University of Washington. In 2003 he joined the faculty at UCSF. Since then he has raised over $200 million in grants and contracts from the NIH, CDC, Bill & Melinda Gates Foundation, Doris Duke Charitable Foundation, Children’s Investment Fund Foundation and through private philanthropy. Dr. Cohen has published over 250 peer-reviewed publications leading to over 14,000 citations. In addition, in 2020 he became the founding editor-in-chief of Advances in Global Health published by UC Press.
Gary Schoolnik, MD
Gary Schoolnik, MD, is Professor of Medicine (Emeritus, Active) in the Department of Medicine, Division of Infectious Diseases at Stanford Medical School. He is also Associate Director of the Institute for Immunology, Transplantation and Infection at the university and is an Attending Physician in Internal Medicine and Infectious Diseases at Stanford University Hospital.
Dr. Schoolnik attended Stanford University. He received his MD degree from the University of Washington in Seattle and was Intern, Resident and Chief Resident in Internal Medicine at the Massachusetts General Hospital in Boston. Dr. Schoolnik was an Associate Physician and Research Associate in microbial biochemistry and genetics at The Rockefeller University in Manhattan before joining the Stanford Medical School faculty.
Dr. Schoolnik’s research has focused on the genetics, genomics and systems biology of pathogenic microbes. He led the Gates Foundation funded tuberculosis genome sequence and bioinformatics database, TBDB.org, and was PI of the NIH-funded Systems Biology of M. tuberculosis international consortium “TBSysBio”. He served on the NIAID National Advisory Council and co-chaired the NIH’s Blue Ribbon Committees on Bioterrorism as well as the committee on the Human Microbiome. Dr. Schoolnik is the founding editor of the journal Molecular Microbiology. While at Stanford he served as Chief of the Division of Infectious Diseases and Geographic Medicine, and as Associate Dean, office of Academic Affairs.
Toni Choueiri, MD
Toni K. Choueiri, MD is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Brigham Cancer Center and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School. He is the Co-Leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center. His work has led to the establishment of several novel and prognostic factors in advanced renal cell carcinoma (RCC). His biomarker work has shed light on complex immunogenomics mechanisms contributing to response and resistance to targeted therapy and immunotherapy. He is the lead investigator of multiple national and international phase I-III trials in GU cancers.